Founder of Versartis, Inc., Targesome, Inc., Diartis Pharmaceuticals, Inc. and Orpheris, Inc., Jeffrey L. Cleland is an entrepreneur and businessperson who has been at the helm of 6 different companies and presently is Executive Chairman, President & CEO at Ashvattha Therapeutics LLC and Executive Chairman for Orpheris, Inc.

He is also Member of American Chemical Society, Member of American Institute of Chemical Engineers and Member of The Controlled Release Society and on the board of 5 other companies.

In the past Jeffrey L. Cleland held the position of President, Chief Executive Officer & Director at Graybug Vision, Inc., Chief Executive Officer & Director at Diartis Pharmaceuticals, Inc., Senior Scientist at Genentech, Inc., President & Chief Executive Officer at Ilypsa, Inc., President, Chief Executive Officer & Director at Versartis, Inc., Vice President-Technical Operations at Novacea, Inc., Vice President-Research & Development at Targesome, Inc., Vice President-Therapeutic Development at BaroFold, Inc. and Member of American Association for the Advancement of Science.

He received a doctorate from Massachusetts Institute of Technology and an undergraduate degree from the University of California, Davis.